Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ORIC Pharmaceuticals Inc.

www.oricpharma.com

Latest From ORIC Pharmaceuticals Inc.

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.

Financing StartUps and SMEs

Appointments: C4 Therapeutics, ORIC Pharma, CytRx, Audentes, Atara, Caribou, Sangamo And Pliant Announce Changes

New appointments announced over the past week include new CEOs at C4 Therapeutics and ORIC pharma, COO at CytRx, President at Audentes, global R&D head at Atara, CBO at Caribou, CTO at Sangamo, and chairman at Pliant.

 

Appointments Leadership

Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?

Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.

Financing Business Strategies

Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.
Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ORIC Pharmaceuticals Inc.
  • Senior Management
  • Richard Heyman, PhD, CEO
    Lori Friedman, PhD, CSO
    Leonard Reyno, MD, CMO
  • Contact Info
  • ORIC Pharmaceuticals Inc.
    Phone: (650) 388-5600
    240 E. Grand Ave.
    2nd Fl.
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register